Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | LY3410738: a first-in-class covalent inhibitor of mutant IDH1 in CCA

Rachna T. Shroff • 7 Jan 2021
ASCO GI 2021
Bile Duct Cancer Gastrointestinal Cancer Cisplatin Gemcitabine Ivosidenib LY3410738

Rachna T. Shroff, MD, University of Arizona Cancer Center, Tucson, AZ, discusses an ongoing Phase I study evaluating LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma (CCA) and other advanced solid tumors. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Rachna T. Shroff

1:59
SWOG 1815: gemcitabine, cisplatin, and nab-paclitaxel in biliary tract cancer
Rachna Shroff et al. • 19 Jan 2023
1:23
Advances in treating biliary tract cancers with targeted therapies
Rachna Shroff et al. • 19 Jan 2023
0:51
Key clinical trial updates from ASCO GI 2023
Rachna Shroff et al. • 19 Jan 2023
1:04
Overcoming resistance to ICIs in biliary tract cancers
Rachna Shroff et al. • 19 Jan 2023

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals